Re: Valentina Tateo, Giuseppe Basile, Patrizia Giannatempo, et al. Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol 2026;90:7–12
- DOI
- 10.1016/j.eururo.2026.08.021
- Published
- 2026-09
- Container
- European Urology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.eururo.2026.08.021,
title = {Re: Valentina Tateo, Giuseppe Basile, Patrizia Giannatempo, et al. Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol 2026;90:7–12},
author = {Ahmed M. Elalfy},
year = {2026},
journal = {European Urology},
doi = {10.1016/j.eururo.2026.08.021},
url = {https://doi.org/10.1016/j.eururo.2026.08.021}
}RIS
TY - JOUR TI - Re: Valentina Tateo, Giuseppe Basile, Patrizia Giannatempo, et al. Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol 2026;90:7–12 AU - Ahmed M. Elalfy PY - 2026 JO - European Urology DO - 10.1016/j.eururo.2026.08.021 UR - https://doi.org/10.1016/j.eururo.2026.08.021 ER -
APA
Elalfy, A. M. (2026). Re: Valentina Tateo, Giuseppe Basile, Patrizia Giannatempo, et al. Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol 2026;90:7–12. European Urology. https://doi.org/10.1016/j.eururo.2026.08.021
Source records
- crossref · retrieved 2026-09-26T07:55:07.207Z